Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Everyone Wins In Deal Between BMS And The Medicines Co.

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.


Related Content

Filings In The Second Half Could Be Transformative For The Medicines Co.
TMC Likes Its Options: Hospital Marketer Gains Rights To ProFibrix
The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets
Start-Up Quarterly Statistics, Q4 2012
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers's Grand Ambitions in Oncology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts